Literature DB >> 18566572

Microarray study of gene expression in uterine leiomyoma.

K V Litovkin1, O V Ivanova, A Bauer, J D Hoheisel, V V Bubnov, V N Zaporozhan.   

Abstract

UNLABELLED: Uterine leiomyoma is a most common benign neoplasm in women of reproductive age. It arises from the myometrial compartment of the uterus and may transform in some cases to a malignant phenotype. AIM: To identify the genes involved in pathogenesis of uterine leiomyoma.
METHODS: We have studied differential gene expression in matched tissue samples of leiomyoma and normal myometrium from the very same people utilizing a cDNA microarray screening method. We also compared our results with previously published microarray data to identify the overlapping gene alterations.
RESULTS: Based on this comparison we can divide genes deregulated in our study into two groups. The first group comprises genes that to our knowledge have not been previously reported as deregulated in fibroids: CLDN1, FGF7 (KGF), HNRPM, ISOC1, MAGEC1 (CT7), MAPK12, RFC, TIE1, TNFRSF21 (DR6). The second group consists of genes identified also in previous studies: CCND1 (BCL1), CDKN1A (P21), CRABP2, FN1 and SOX4 (EVI16). In our study FN1 was the most up-regulated gene, occupying the place between the myometrium and fibroids ranging from 2.07 to 3.64, depending of the probe molecule used for detection.
CONCLUSIONS: Newly identified genes may be regarded as potential diagnostic or prognostic markers of uterine leiomyoma and thus may be very useful as new therapeutic candidates.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18566572

Source DB:  PubMed          Journal:  Exp Oncol        ISSN: 1812-9269


  8 in total

1.  Increased expression of SOX4 is a biomarker for malignant status and poor prognosis in patients with non-small cell lung cancer.

Authors:  Dingmiao Wang; Ting Hao; Yang Pan; Xiaowei Qian; Daixing Zhou
Journal:  Mol Cell Biochem       Date:  2015-01-08       Impact factor: 3.396

2.  Subtype-Specific Tumor-Associated Fibroblasts Contribute to the Pathogenesis of Uterine Leiomyoma.

Authors:  Xin Wu; Vanida A Serna; Justin Thomas; Wenan Qiang; Michael L Blumenfeld; Takeshi Kurita
Journal:  Cancer Res       Date:  2017-10-20       Impact factor: 12.701

3.  A high concentration of genistein down-regulates activin A, Smad3 and other TGF-β pathway genes in human uterine leiomyoma cells.

Authors:  Xudong Di; Danica M K Andrews; Charles J Tucker; Linda Yu; Alicia B Moore; Xiaolin Zheng; Lysandra Castro; Tonia Hermon; Hang Xiao; Darlene Dixon
Journal:  Exp Mol Med       Date:  2012-04-30       Impact factor: 8.718

4.  A G-quadruplex DNA structure resolvase, RHAU, is essential for spermatogonia differentiation.

Authors:  X Gao; W Ma; J Nie; C Zhang; J Zhang; G Yao; J Han; J Xu; B Hu; Y Du; Q Shi; Z Yang; X Huang; Y Zhang
Journal:  Cell Death Dis       Date:  2015-01-22       Impact factor: 8.469

5.  Knockdown of ISOC1 inhibits the proliferation and migration and induces the apoptosis of colon cancer cells through the AKT/GSK-3β pathway.

Authors:  Bo Gao; Lianmei Zhao; Feifei Wang; Hanyu Bai; Jing Li; Meng Li; Xuhua Hu; Jian Cao; Guiying Wang
Journal:  Carcinogenesis       Date:  2020-08-12       Impact factor: 4.944

6.  Impact of Genetic Variants in Estrogen Receptor-β Gene in the Etiology of Uterine Leiomyomas.

Authors:  Chitroju Bharathi; Desamala Anupama; Nallari Pratibha; Anantapur Venkateshwari
Journal:  J Reprod Infertil       Date:  2019 Jul-Sep

7.  Isochorismatase domain-containing protein 1 (ISOC1) participates in DNA damage repair and inflammation-related pathways to promote lung cancer development.

Authors:  Jinghan Shi; Fujun Yang; Nanfeng Zhou; Yan Jiang; Yanfeng Zhao; Junjie Zhu; Arsela Prelaj; Jyoti Malhotra; Nicola Normanno; Elisa Danese; Andrés F Cardona; Xuan Hong; Gening Jiang; Xiao Song
Journal:  Transl Lung Cancer Res       Date:  2021-03

8.  Fibronectin 1 inhibits the apoptosis of human trophoblasts by activating the PI3K/Akt signaling pathway.

Authors:  Jinlong Ji; Liping Chen; Yanyan Zhuang; Yun Han; Weichun Tang; Fei Xia
Journal:  Int J Mol Med       Date:  2020-09-23       Impact factor: 4.101

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.